UMIN-CTR History

Name：　　UMIN ID：


Unique ID issued by UMIN UMIN000013928
Receipt number R000016241
Scientific Title Phase II study of Eribulin every other week maintenance therapy, after induction therapy of Eribulin on day1 and 8 for 3 cycles, in patients with hormone receptor positive and HER2-negative advanced recurrent breast cancer.
Date of disclosure of the study information 2014/05/13
Last modified on 2019/03/22 10:43:36

No. Disposal Last modified on Item of update
1 Insert 2014/05/12 09:35:30
2 Update 2016/11/15 13:34:42 Interventions/Control_1
Key inclusion criteria
3 Update 2016/11/15 13:35:08 Name of primary person or sponsor
Organization
4 Update 2016/11/15 13:36:05 Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Publication of results
5 Update 2018/01/17 12:03:49 Recruitment status
6 Update 2019/03/22 10:39:54 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code

Last name of contact person

Last name of contact person
Zip code
Organization
Organization
Address
Address
Tel
Email
7 Update 2019/03/22 10:40:45 Number of participants that the trial has enrolled
8 Update 2019/03/22 10:43:36 Recruitment status
Date of IRB
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded